8-K: Liminatus Pharma Completes InnocsAI Acquisition

Liminatus Pharma, Inc. has finalized its acquisition of InnocsAI LLC, amending the merger agreement to include convertible preferred stock as part of the consideration.

Summary

• Liminatus Pharma, Inc. (the Company) has completed its acquisition of InnocsAI LLC through a merger with a newly formed subsidiary.
• The original merger agreement, dated May 17, 2026, was amended and restated on June 29, 2026.
• The revised agreement allows for closing before stockholder approval and alters the merger consideration.
• InnocsAI members will receive a combination of the Company's common stock and newly designated Series A Non-Voting Convertible Preferred Stock.
• The common stock portion is capped at approximately 19.99% of the Company's outstanding shares immediately prior to closing.
• The Series A Preferred Stock is convertible into common stock, but only after stockholder approval is obtained.
• The Company intends to hold a stockholder meeting to approve the issuance of common stock upon conversion of the Series A Preferred Stock.
• Ancillary agreements include a registration rights agreement for the former InnocsAI members and a non-competition and non-solicitation agreement with key InnocsAI employees.
• The merger officially closed on July 2, 2026.
• In connection with the closing, 11,188,729 shares of common stock and 158,881.1271 shares of Series A Preferred Stock were issued to former InnocsAI members.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, reflecting the completion of a strategic acquisition that expands Liminatus Pharma's capabilities in CAR-T therapy. However, the reliance on future stockholder approval for full conversion of preferred stock and the noted need for additional capital introduce some uncertainty.

Positives

• Completion of the acquisition of InnocsAI, a company involved in CAR-T therapy technologies.
• Restructuring of the merger consideration to include convertible preferred stock, potentially allowing for a faster closing and managing immediate dilution.
• Secured ancillary agreements, including non-competition and non-solicitation clauses, to protect the acquired business and its value.
• The company has established a clear path for stockholder approval of the preferred stock conversion, indicating a commitment to corporate governance.
• The issuance of shares was made pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act.

Negatives

• The issuance of a significant amount of convertible preferred stock requires future stockholder approval, creating a potential overhang.
• The convertible preferred stock is not convertible until stockholder approval is obtained, delaying the full conversion of consideration into common stock.
• The company's ability to fund planned programs and operations and continue as a going concern is dependent on additional capital, as noted in the forward-looking statements.
• The company must maintain compliance with Nasdaq continued listing requirements to prevent delisting.

Risks

• The risk that the required approval of the Company's stockholders for the issuance of common stock upon conversion of the Series A Preferred Stock is not obtained.
• The Company's need for additional capital to fund its planned programs and operations and to continue to operate as a going concern.
• Failure to realize the anticipated benefits of the proposed transactions, including as a result of a delay in consummating the proposed transactions.
• Risks relating to the Company's sources of cash and cash resources.
• Risks relating to the Company's ability to manage future growth.
• The effects of competition on the Company's future business.
• The Company's ability to maintain compliance with Nasdaq continued listing requirements in order to prevent its common stock from being delisted.
• The outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries involving the Company.
• The impact of pandemics, global conflicts, the global economic status or tariffs on the Company's business.

Future Outlook

The Company intends to hold a meeting of its stockholders to approve the issuance of common stock issuable upon conversion of the Series A Preferred Stock. The forward-looking statements section highlights the Company's need for additional capital and its ability to manage future growth, alongside risks related to competition, Nasdaq listing compliance, and potential litigation.

Industry Context

StockSavvy.ai notes that the acquisition of InnocsAI, a CAR-T therapy technology company, by Liminatus Pharma aligns with the ongoing trend of consolidation and strategic partnerships within the biotechnology sector, particularly in the oncology space. Companies are increasingly seeking to bolster their pipelines and technological capabilities through M&A.

Corporate Governance

Related Party Transactions

• The merger agreement was entered into between Liminatus Pharma, Inc. and InnocsAI LLC, with NamChul Jung acting as the representative of InnocsAI's members.
• A non-competition and non-solicitation agreement was entered into between InnocsAI and certain key employees of InnocsAI for the benefit of Liminatus Pharma and its affiliates.
• A registration rights agreement was entered into between Liminatus Pharma and the existing members of InnocsAI.

Stakeholder Impact

• Shareholders of Liminatus Pharma: Will be subject to a vote on the issuance of common stock upon conversion of the Series A Preferred Stock. Potential dilution from the conversion of preferred stock is a key consideration.
• Former InnocsAI Members: Will receive a combination of common and convertible preferred stock, with registration rights for their shares.
• Employees of InnocsAI: Key employees are subject to non-competition and non-solicitation agreements for two years post-merger.
• Creditors: No immediate direct impact mentioned, but future capital needs could affect financial leverage.

Next Steps

• Liminatus Pharma will hold a meeting of its stockholders to approve the issuance of common stock upon conversion of the Series A Preferred Stock.
• The company will file a proxy statement with the SEC in connection with the stockholder vote.
• The former InnocsAI members will receive registration rights for their shares.
• Key employees of InnocsAI will be bound by non-competition and non-solicitation agreements for two years post-merger.

Key Dates

Recommendation

Keywords

Liminatus Pharma, InnocsAI, Merger Agreement, Acquisition, CAR-T therapy, Convertible Preferred Stock, Stockholder Approval, SEC Filing, Form 8-K, Registration Rights, Non-Compete Agreement